Earnings Call Summary | Owlet Inc(OWLT.US) Q4 2023 Earnings Conference
Earnings Call Summary | Owlet Inc(OWLT.US) Q4 2023 Earnings Conference
The following is a summary of the Owlet, Inc. (OWLT) Q4 2023 Earnings Call Transcript:
以下是Owlet, Inc.（OWLT）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Owlet reported Q4 revenue of $21 million.
The company achieved nearly breakeven adjusted EBITDA by the end of 2023.
Operating expenses were significantly reduced by 60% and marketing expenses by 70%.
There was a 1,900 basis points year-over-year improvement in gross margins to 47% in Q4.
Gross billings for Q4 and full year were $32.9 million and $73.2 million, respectively.
Operating expenses in Q4 were at $13 million, a 46% decrease year-over-year.
Net loss for Q4 was $6.9 million, a 65% decrease from Q4 2022.
The company has a target gross margin within the range of 45% to 50% through unit volume, product mix, and ongoing operational efficiencies.
Owlet公佈的第四季度收入爲2100萬美元。
到2023年底，該公司在調整後的息稅折舊攤銷前利潤幾乎實現了盈虧平衡。
運營費用顯著減少了60％，營銷費用減少了70％。
第四季度毛利率同比增長1,900個點子至47％。
第四季度和全年的總賬單分別爲3,290萬美元和7,320萬美元。
第四季度的運營支出爲1300萬美元，同比下降46％。
第四季度的淨虧損爲690萬美元，比2022年第四季度下降了65％。
通過單位產量、產品組合和持續運營效率，該公司的目標毛利率在45％至50％之間。
Business Progress:
業務進展：
Owlet launched BabySat and Dream Sock with medical-grade features and secured FDA clearances.
Owlet became the 1st and only FDA cleared baby monitor in its category.
Key channels reduced weeks on hand and improved sell-through, improving by over 45% over the year.
Plans for European expansion in 2024, beginning with CE Medical clearance, are in place.
Owlet intends to launch new software and services to better leverage their extensive infant health data.
The company is focusing on maximizing Dream products and maintaining sell-in and sell-through retail inventory balance.
New DME partnerships are expected to increase revenue as these partnerships solidify in 2024.
The company is financially supported by its largest investors and banking and trade partners.
Owlet 推出了具有醫療級功能並獲得 FDA 許可的 BabySat 和 Dream Sock。
Owlet 成爲該類別中第一款也是唯一一款經美國食品藥品管理局批准的嬰兒監護器。
關鍵渠道減少了手頭週數，提高了銷售量，同比增長了45％以上。
2024年的歐洲擴張計劃已經到位，首先是CE醫療許可。
Owlet打算推出新的軟件和服務，以更好地利用其廣泛的嬰兒健康數據。
該公司專注於最大限度地利用夢想產品，維持賣入和銷售的零售庫存餘額。
隨着這些合作伙伴關係在2024年得到鞏固，新的DME合作伙伴關係預計將增加收入。
該公司由其最大的投資者以及銀行和貿易伙伴提供財務支持。
More details: Owlet inc IR
更多詳情： Owlet inc IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。